FeaturedMedia Release
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP)
FeaturedMedia Release
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy
Featured
Finance News Network interviews CEO Peter Molloy
CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology’s
FeaturedMedia Release
Race appoints US consultant to drive partnering, investment, clinical funding
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to
FeaturedMedia Release
Race signs agreement with NSF Health Sciences to file IND
Race Oncology is pleased to announce it has executed an agreement with Washington D.C –
FeaturedMedia Release
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that
FeaturedMedia Release
Chart: Long-term survival case report of patients treated with Bisantrene Combination Therapy
The chart below details the long-term survival case report of two paediatric relapsed or
FeaturedMedia Release
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and
FeaturedMedia Release
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene
Featured
Proactive Investor interviews John Cullity
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the